Brook Byers


Dr. Brook H. Byers, Ph.D., is a Partner at KPCB Digital Growth Fund, L.P., Kleiner Perkins Caufield & Byers XI, L.P., Kleiner Perkins Caufield & Byers XII, L.P., Kleiner Perkins Caufield & Byers XIII, L.P. and KPCB Information Sciences Zaibatsu Fund II, L.P. Dr. Byers is a part of pandemic and biodefense and life sciences team. Dr. Byers formed the first venture capital Life Science Practice Group in 1984, helping it to become a premier venture capital firm in the medical, healthcare, and biotechnology fields. He served as the founding President and then the Chairman of four biotechnology companies incubated in its office. Dr. Byers has been a venture capital investor since 1972 and has been closely involved with more than 50 new technology based companies over half of which have already become public companies. He was a Founder at TechNet.Brook. He served as the President and Director of the Western Association of Venture Capitalists. He serves as the Chairman of OptiMedica Corporation. He served as the Chairman of Biogen Idec Inc., Idec Pharmaceuticals, Ligand Pharmaceuticals, Hybritech, Athena Neurosciences and That Man May See (UCSF) Vision Research Foundation. He served as a Co-Chairman of the UCSF Capital Campaign. He served as the Chairman of XDx, Inc. and has been its Director since January 2003. He has been a Director of Pacific Biosciences, Inc., since 2004 and Argonaut Technologies Inc. since January 1995. Dr. Byers serves as a Director of Gen-Probe Inc., Crescendo Bioscience, Inc., Foundation Medicine, Inc., MDV-Mohr Davidow Ventures, Reily Genomics, CardioDX, Optimedia, Tethys Bioscience, Inc., Xilogy and NewSchools Venture Fund, Investment Arm. He serves as Board Trustee at Stanford University. Dr. Byers serves as a Board Member of the University of California at San Francisco Medical Foundation, New Schools Foundation, Stanford’s Bio-X Advisory Council, and the Stanford Eye Council. Dr. Byers also serves as a Member of Advisory Board of eVolution Global Partners, L.L.C. Dr. Byers served as a Director of Signal Pharmaceuticals, Pharmacopeia, Onyx Pharmaceuticals, Arris Pharmaceuticals, Genprobe, Nanogen, Insite Vision Inc. and others. He served as a Director of Genomic Health Incorporated, iScribe, Inc., Accelrys Inc., Five Prime Therapeutics, Inc., Celgene Research Division, AXYS Pharmaceuticals, Inc., the Entrepreneurs Foundation, California Healthcare Institute, Asian Art Museum in San Francisco, Stanford Graduate School of Business Advisory Council, and Georgia Tech Advisory Board. Dr. Byers is a Member of Investment Advisory Committee of Mission Bay Capital LLC. In 2009, Dr. Byers received the Lifetime Achievement Award from the National Venture Capital Association. In 2008, he was elected a Fellow of the American Academy of Arts and Sciences. In 2007, Dr. Byers was awarded the UCSF Medal as their honorary degree equivalent. He is a contributing author of the book Guide to Venture Capital. In May, 2010, Dr. Byers received an Honorary Ph.D. in Electrical Engineering from Georgia Tech. He holds an MBA degree from Stanford and BS in Electrical Engineering from Georgia Tech.

Source: Bloomberg Businessweek

Interview – January 1, 2006

Interviewed by Thomas D. Kiley

Provided courtesy of the UC Berkeley Bancroft Library Program in the History of the Biological Sciences and Biotechnology.